GenAI in Healthcare: CISO & CMO Deployment Guide

Learn how healthcare CISOs and CMOs can assess GenAI deployments on clinical data, covering PHI security, HIPAA compliance, clinical validation, liability, and AI governance.

A GenAI vendor demo goes well. The CISO in the room asks about data residency and gets a satisfactory answer about which region the servers sit in. The CMO in the room asks about clinical accuracy and gets a satisfactory answer about validation statistics. Both sign off. Six months into production, the organization discovers two things nobody had specifically asked about: patient notes were being used to further train the vendor’s general-purpose model unless an opt-out was separately requested and configured, and the model’s confidence scoring had never been validated against the specific specialty mix of this organization’s patient population, which turned out to matter a great deal for a service line that represented a third of the deployment’s intended use.

Neither of these gaps was a failure of the CISO’s security review or the CMO’s clinical review individually. Each reviewer asked good questions within their own domain. The gap existed in between the two domains, in the set of questions that only make sense when security and clinical perspectives are combined — questions about what happens to data used for model improvement, which is a security and governance question, but also directly determines clinical liability exposure, which is a CMO concern. Questions about validation subgroups, which sound like a clinical concern, but which also determine whether the security team’s risk classification for this deployment was even set correctly in the first place.

GenAI on clinical data needs a joint sign-off process, not two separate sign-offs conducted in parallel by teams that never actually compare notes on where their questions overlap. This article lays out the specific questions each side should bring to that joint review, and — more importantly — the questions that live at the intersection and get missed when the two reviews happen independently.

The CISO’s Questions

Where does the data actually go, physically and contractually? This means the specific hosting region, the specific list of subprocessors who might touch the data, and the specific retention period after which data is deleted rather than indefinitely retained. Vendors are frequently vague on subprocessor lists in particular, treating them as an appendix nobody reads rather than information a security team needs to evaluate directly.

Is PHI used for further model training, and can that be explicitly disabled in writing? This is the single most consequential question in the entire GenAI clinical data conversation and the one most likely to be answered ambiguously in a sales conversation. Many general-purpose AI platforms default to using submitted data for ongoing model improvement unless an enterprise customer specifically negotiates an opt-out, and that opt-out needs to be a contractual term, not a verbal assurance from a sales engineer who may not actually know the platform’s default configuration.

What is the breach notification SLA, measured in hours rather than the vague ‘promptly’ language common in vendor contracts, and who calls whom first when an incident occurs? Can every prompt sent to the model and every output received be logged and audited, with that log retained per the organization’s own record retention policy rather than the vendor’s shorter default? What is the access control model, and does it integrate with the organization’s existing identity and access management system rather than requiring a separate credential set that inevitably becomes a security blind spot over time? Has a recent third-party penetration test been conducted, and will the vendor share the full report rather than a marketing summary that omits the findings that actually matter?

Each of these questions is standard security due diligence, well understood by any competent CISO. The failure mode is not that these questions don’t get asked; it is that they get asked and answered in a security-only review that never surfaces its findings to the clinical team, who might have caught that a training-data policy gap has direct implications for clinical liability, or that a retention-period answer has implications for what happens to a flagged low-confidence extraction that a clinician never got around to reviewing.

The CMO’s Questions

What specific clinical judgment does this GenAI capability touch, and exactly where is the line between assisting a clinician’s decision and making the decision itself? This line needs to be drawn explicitly, in writing, before deployment, not discovered implicitly through how clinicians end up using the tool in practice. Was this model validated on patients who look like ours, broken out by the demographic and clinical subgroups that matter for our population, rather than an aggregate accuracy number that could be hiding meaningfully worse performance on the subgroups our specific patient population is concentrated in?

How does a clinician override an output they believe is wrong, and is that override a single frictionless click with no professional penalty attached, or a cumbersome process that quietly discourages clinicians from exercising the judgment the whole system depends on them retaining? Who specifically reviews low-confidence extractions that the model itself has flagged as uncertain, and what is the defined turnaround time for that review — because an extraction correctly flagged as uncertain provides no safety value if it then sits unreviewed in a queue for two weeks?

What is the confirmed malpractice and liability posture for decisions influenced by this tool, verified directly with risk management and the malpractice carrier rather than assumed based on how similar tools have been treated in the past? And, critically: can a clinician actually explain this tool’s role to a patient in plain, honest language, in a way that would hold up if that explanation were later scrutinized by a regulator or reported publicly? If the honest answer to that last question is uncertain, the deployment is not ready regardless of how strong the underlying model’s accuracy statistics look.

Where the Two Reviews Have to Meet

The most dangerous gaps are not inside either review; they are in the space between the two reviews, where a question that sounds like it belongs entirely to one domain actually has consequences that only the other domain would recognize. The training-data question is the clearest example: it reads as a security and contracts question, and a CISO evaluating it purely on data-governance terms might reasonably conclude that using de-identified data for model improvement carries acceptable risk. But if that same de-identified data can be re-identified in combination with the clinical narrative content — a real risk with detailed clinical notes — the clinical liability exposure is significant, and that exposure is not something a security review alone is positioned to catch.

The validation-subgroup question runs the same risk in reverse. A CMO evaluating clinical validation data might reasonably focus on whether the model performs well on the specific conditions and specialties it will be used for. But whether that validation data itself was handled with appropriate security controls, whether the subgroup analysis reveals a bias pattern that also constitutes a regulatory or reputational risk, and whether the vendor’s willingness (or refusal) to share granular validation data is itself a security transparency signal — these are dimensions a purely clinical review may not weight properly.

The practical fix is straightforward: run one joint review session, not two sequential sign-offs, where the CISO and CMO (or their delegates) go through both question sets together in the same room, explicitly looking for the questions that only make sense when both lenses are applied simultaneously. This session does not need to be lengthy — most organizations that do this well complete it in two to three hours — but it needs to happen before either party signs off independently, not as a follow-up conversation after both have already given informal approval based on their own domain review.

Where This Joint Review Fits in the Broader Governance Process

This joint CISO-CMO review is not a substitute for the broader AI governance structure a healthcare organization should already have in place — it is a specific, specialized instance of that structure applied to the particular risk profile GenAI on clinical data presents. Organizations with a mature AI governance operating model already have an ethics review process, a risk classification framework, and an incident response protocol; the joint review described here slots into that structure as the domain-specific analysis feeding the ethics review board’s decision, rather than replacing it. Organizations without that broader structure yet should treat building this joint review as a natural first step toward the more complete governance model, since the collaboration pattern it establishes between security and clinical leadership is exactly the pattern that broader AI governance depends on.

It is also worth being explicit that this review is not a one-time event tied only to initial deployment. Vendor contracts change. Vendors get acquired, and the acquiring company’s data practices may differ from what was originally negotiated. Model versions get updated, sometimes silently, in ways that shift performance on your specific patient subgroups without any notification unless you are specifically monitoring for it. A responsible practice is to re-run an abbreviated version of this joint review annually for every active GenAI deployment touching clinical data, and immediately whenever the vendor announces a material change to their platform, their subprocessor list, or their model architecture. The organizations most likely to be caught off guard by a GenAI clinical data incident are not the ones who skipped the initial review; they are the ones who did the initial review well and then assumed that approval was permanent.

What a Complete Sign-Off Actually Looks Like

A complete GenAI clinical data sign-off produces a single document, not two separate memos filed in different systems, that names the specific answer to every question above, cites the specific contractual language or technical evidence supporting that answer, and is co-signed by both the CISO (or delegate) and the CMO (or delegate). This document should specify exactly what data flows where, exactly what clinical decisions the tool touches and does not touch, exactly how overrides and low-confidence flags are handled operationally, and exactly what the liability and disclosure posture is. It should take real time to produce — typically two to four weeks once both teams are actively engaged, not a same-week rubber stamp squeezed in around a launch date that was set before the review began. Organizations that build this joint review into their standard process for any GenAI deployment touching clinical data consistently catch the intersection risks that purely parallel reviews miss, and they enter production with a document that holds up when a regulator, a patient’s attorney, or an internal audit asks exactly what was known and approved before go-live, and why. That single document becomes the reference point every subsequent audit, incident review, or renewal conversation returns to, which is exactly the point.

About BTC

BTC helps healthcare organizations run joint CISO-CMO readiness reviews before GenAI touches clinical data — surfacing the intersection risks that separate security and clinical sign-offs routinely miss.

Comments

Your healthcare program deserves
all the advantages that digital technology delivers.

Get A Free Consultation